e-Article
Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience.
Document Type
Article
Author
Source
Subject
*PROSTATE cancer patients
*PROSTATE cancer treatment
*DRUG side effects
*IPILIMUMAB
*T cells
*CLINICAL trials
*IMMUNOTHERAPY
*THERAPEUTICS
*PHYSIOLOGY
*
*
*
*
*
*
*
*
Language
ISSN
0950-9232
Abstract
Targeting a T-cell inhibitory checkpoint with the anti-CTLA-4 monoclonal antibody, ipilimumab, represents a scientific breakthrough in immunotherapy for the treatment of cancer. However, ipilimumab therapy is also associated with unique side effects, known as immune-related adverse events (irAEs), which need to be recognized and managed with immunosuppressive agents. To date, the majority of our knowledge regarding ipilimumab-associated side effects is based upon clinical studies in melanoma. Here we provide a review of ipilimumab-induced irAEs and our experience in a cohort of 44 patients with prostate cancer who were treated at the MD Anderson Cancer Center on two different clinical trial protocols. [ABSTRACT FROM AUTHOR]